Teligene is a drug discovery company focused on developing small-molecule therapeutics using advanced computational chemistry and high-throughput screening techniques. The company addresses the need for more effective treatments by accelerating the identification and optimization of drug candidates for various diseases.
Funding
Funding not disclosed
Founders
Product
Problem
The traditional drug discovery process is often slow, expensive, and inefficient, requiring significant time and resources to identify and optimize promising drug candidates. This lengthy process can delay the development of effective treatments for various diseases.
Solution
Teligene employs advanced computational chemistry and high-throughput screening techniques to accelerate the identification and optimization of small-molecule therapeutics. By leveraging computational methods, the company aims to streamline the drug discovery process, reduce development timelines, and increase the likelihood of identifying effective drug candidates for a range of diseases. This approach enables faster and more efficient development of potential treatments.
Target Audience
Teligene's primary customers are pharmaceutical companies and research institutions seeking to accelerate their drug discovery efforts and identify promising therapeutic candidates.
Features
- Utilizes advanced computational chemistry techniques for in-silico drug design.
- Employs high-throughput screening to rapidly evaluate a large number of potential drug candidates.
- Focuses on developing small-molecule therapeutics.